Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Oculus device receives FDA premarket approval
The FDA has granted premarket approval to a new pachymeter/auto-refractor/keratometer (PARK 1, Oculus).
Key Points
Lynwood, WA-The FDA has granted premarket approval to a new pachymeter/auto-refractor/keratometer (PARK 1, Oculus).
The device was launched at the annual meeting of the American Academy of Ophthalmology in Atlanta.
The instrument is designed to photograph the eye and obtain a Scheimpflug image of the cornea to evaluate its thickness, according to the company. The implanted ophthalmic refractometer measures the refractive power of the eye.
Related Videos
Related Content
